CELG INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Celgene Corporation Investors

BENSALEM, Pa.--()--Law Offices of Howard G. Smith continues its investigation on behalf of Celgene Corporation (“Celgene” or the “Company) (NASDAQ: CELG) investors concerning the Company and its officers’ possible violations of federal securities laws.

“Company) (NASDAQ: CELG) investors concerning the Company and its officers’ possible violations of federal securities laws.”

On February 27, 2018, Celgene announced that the FDA rejected the Company’s New Drug Application (“NDA”) for Ozanimod, a treatment for multiple sclerosis. Celgene stated that it had received a refusal-to-file letter from the FDA, which advised the Company that the FDA had “determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review.” On this news, Celgene’s share price fell $8.66, or 9%, on February 28, 2018, thereby injuring investors.

If you purchased Celgene securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Recent Stories

RSS feed for Law Offices of Howard G. Smith

Release Summary

CELG INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Celgene Corporation Investors

Law Offices of Howard G. Smith